Dingdang Health Technology Group Ltd. (HK:9886)
:9886
Want to see HK:9886 full AI Analyst Report?
9886 Stock Chart & Stats
HK$1.08
-HK$0.02(-3.23%)
At close: 4:00 PM EST
HK$1.08
-HK$0.02(-3.23%)
Day’s Range― - ―
52-Week RangeHK$0.46 - HK$1.37
Previous CloseN/A
Volume431.00K
Average Volume (3M)4.91M
Market Cap
HK$1.11B
Enterprise ValueHK$721.01M
Total Cash (Recent Filing)HK$1.36B
Total Debt (Recent Filing)HK$263.13M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,254,649,400
10 Day Avg. Volume8,114,443
30 Day Avg. Volume4,906,414
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)HK$6.85B
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Improving MarginsA 70% revenue rebound alongside a higher gross margin (~35.3%) indicates the core O2O pharmacy model is regaining traction and achieving better unit economics. Durable top-line recovery with margin expansion improves operating leverage and the path to sustained profitability if execution continues.
Positive Operating And Free Cash FlowThe swing to positive operating cash flow (~155M) and free cash flow (~123M) materially improves financial flexibility, enabling reinvestment in delivery, stores, and tech without immediate external funding. If sustained, positive FCF supports organic growth and lowers refinancing risk.
Manageable Leverage And Stronger Balance SheetLow recent leverage and positive equity through 2022–2025 provide resilience versus peers with higher debt. A conservative balance sheet affords capacity for strategic investment, weathering cyclical shocks, and optionality for partnerships or selective M&A as the business scales.
Bears Say
Still Slightly UnprofitableAlthough losses narrowed, remaining negative net margins mean the company has not yet demonstrated consistent profitability. Persistent subpar returns can limit reinvestment capacity, raise the need for external capital, and leave outcomes dependent on continued operational improvement.
Cash Flow Volatility HistoricallyPrior multi-year negative cash flows indicate volatility in cash conversion; the 2025 improvement may reflect timing or working-capital effects. Such swings increase financing uncertainty and make it harder to rely on cash generation for long-term investments or to absorb shocks.
Negative Returns On Equity & Past Balance-sheet StressNegative ROE through 2025 and historical episodes of negative equity highlight past execution and capital efficiency problems. This legacy reduces investor confidence and implies management must sustain operational gains to convert improved results into durable returns on shareholder capital.
Dingdang Health Technology Group Ltd. News
9886 FAQ
What was Dingdang Health Technology Group Ltd.’s price range in the past 12 months?
Dingdang Health Technology Group Ltd. lowest stock price was HK$0.46 and its highest was HK$1.37 in the past 12 months.
What is Dingdang Health Technology Group Ltd.’s market cap?
Dingdang Health Technology Group Ltd.’s market cap is HK$1.11B.
When is Dingdang Health Technology Group Ltd.’s upcoming earnings report date?
Dingdang Health Technology Group Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 69 days.
How were Dingdang Health Technology Group Ltd.’s earnings last quarter?
Dingdang Health Technology Group Ltd. released its earnings results on Mar 20, 2026. The company reported HK$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.002.
Is Dingdang Health Technology Group Ltd. overvalued?
According to Wall Street analysts Dingdang Health Technology Group Ltd.’s price is currently Overvalued.
Does Dingdang Health Technology Group Ltd. pay dividends?
Dingdang Health Technology Group Ltd. does not currently pay dividends.
What is Dingdang Health Technology Group Ltd.’s EPS estimate?
Dingdang Health Technology Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dingdang Health Technology Group Ltd. have?
Dingdang Health Technology Group Ltd. has 1,254,649,400 shares outstanding.
What happened to Dingdang Health Technology Group Ltd.’s price movement after its last earnings report?
Dingdang Health Technology Group Ltd. reported an EPS of HK$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.205%.
Which hedge fund is a major shareholder of Dingdang Health Technology Group Ltd.?
Currently, no hedge funds are holding shares in HK:9886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dingdang Health Technology Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.00%
12-Months-Change
Fundamentals
Return on Equity
-2.95%
Trailing 12-Months
Asset Growth
12.67%
Trailing 12-Months
Company Description
Dingdang Health Technology Group Ltd.
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is based in Beijing, China.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Cheerwin Group Limited
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―
Options Prices
Currently, No data available
---